

Frederik Persson

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/594689/publications.pdf>

Version: 2024-02-01

143
papers

10,272
citations

81743

39
h-index

35952

97
g-index

148
all docs

148
docs citations

148
times ranked

10811
citing authors

#	ARTICLE	IF	CITATIONS
1	2019 ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD. <i>European Heart Journal</i> , 2020, 41, 255-323.	1.0	2,811
2	Cardiorenal End Points in a Trial of Aliskiren for Type 2 Diabetes. <i>New England Journal of Medicine</i> , 2012, 367, 2204-2213.	13.9	1,145
3	Aliskiren Combined with Losartan in Type 2 Diabetes and Nephropathy. <i>New England Journal of Medicine</i> , 2008, 358, 2433-2446.	13.9	1,051
4	Cardiovascular mortality and morbidity in patients with type 2 diabetes following initiation of sodium-glucose co-transporter-2 inhibitors versus other glucose-lowering drugs (CVD-REAL Nordic): a multinational observational analysis. <i>Lancet Diabetes and Endocrinology</i> , 2017, 5, 709-717.	5.5	285
5	Urinary Proteomics for Early Diagnosis in Diabetic Nephropathy. <i>Diabetes</i> , 2012, 61, 3304-3313.	0.3	221
6	Diagnosis and Prediction of CKD Progression by Assessment of Urinary Peptides. <i>Journal of the American Society of Nephrology: JASN</i> , 2015, 26, 1999-2010.	3.0	205
7	Diagnosis of diabetic kidney disease: state of the art and future perspective. <i>Kidney International Supplements</i> , 2018, 8, 2-7.	4.6	202
8	Early detection of diabetic kidney disease by urinary proteomics and subsequent intervention with spironolactone to delay progression (PRIORITY): a prospective observational study and embedded randomised placebo-controlled trial. <i>Lancet Diabetes and Endocrinology</i> , 2020, 8, 301-312.	5.5	166
9	Dapagliflozin is associated with lower risk of cardiovascular events and all-cause mortality in people with type 2 diabetes (CVD-REAL Nordic) when compared with dipeptidyl peptidase-4 inhibitor therapy: multinational observational study. <i>Diabetes, Obesity and Metabolism</i> , 2018, 20, 344-351.	2.2	164
10	Implementation of proteomic biomarkers: making it work. <i>European Journal of Clinical Investigation</i> , 2012, 42, 1027-1036.	1.7	151
11	Renal Effects of Aliskiren Compared With and in Combination With Irbesartan in Patients With Type 2 Diabetes, Hypertension, and Albuminuria. <i>Diabetes Care</i> , 2009, 32, 1873-1879.	4.3	147
12	A urinary peptide biomarker set predicts worsening of albuminuria in type 2 diabetes mellitus. <i>Diabetologia</i> , 2013, 56, 259-267.	2.9	128
13	Time course of the antiproteinuric and antihypertensive effects of direct renin inhibition in type 2 diabetes. <i>Kidney International</i> , 2008, 73, 1419-1425.	2.6	121
14	YKL-40, a Marker of Inflammation and Endothelial Dysfunction, Is Elevated in Patients With Type 1 Diabetes and Increases With Levels of Albuminuria. <i>Diabetes Care</i> , 2009, 32, 323-328.	4.3	117
15	Differential Effects of Dapagliflozin on Cardiovascular Risk Factors at Varying Degrees of Renal Function. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2017, 12, 751-759.	2.2	114
16	The dapagliflozin and prevention of adverse outcomes in chronic kidney disease (DAPA-CKD) trial: baseline characteristics. <i>Nephrology Dialysis Transplantation</i> , 2020, 35, 1700-1711.	0.4	107
17	Multicentre prospective validation of a urinary peptidome-based classifier for the diagnosis of type 2 diabetic nephropathy. <i>Nephrology Dialysis Transplantation</i> , 2014, 29, 1563-1570.	0.4	106
18	Proteomic prediction and Renin angiotensin aldosterone system Inhibition prevention Of early diabetic nephropathy in Type 2 diabetic patients with normoalbuminuria (PRIORITY): essential study design and rationale of a randomised clinical multicentre trial. <i>BMJ Open</i> , 2016, 6, e010310.	0.8	103

#	ARTICLE	IF	CITATIONS
19	Arterial Stiffness Is Associated With Cardiovascular, Renal, Retinal, and Autonomic Disease in Type 1 Diabetes. <i>Diabetes Care</i> , 2013, 36, 715-721.	4.3	99
20	Progressive Decline in Estimated Glomerular Filtration Rate in Patients With Diabetes After Moderate Loss in Kidney Function—Even Without Albuminuria. <i>Diabetes Care</i> , 2019, 42, 1886-1894.	4.3	99
21	Intensified multifactorial intervention in type 2 diabetics with microalbuminuria leads to long-term renal benefits. <i>Kidney International</i> , 2017, 91, 982-988.	2.6	80
22	Irbesartan Treatment Reduces Biomarkers of Inflammatory Activity in Patients With Type 2 Diabetes and Microalbuminuria: An IRMA 2 Substudy. <i>Diabetes</i> , 2006, 55, 3550-3555.	0.3	77
23	The effect of liraglutide on renal function: A randomized clinical trial. <i>Diabetes, Obesity and Metabolism</i> , 2017, 19, 239-247.	2.2	77
24	Microalbuminuria: A parameter that has changed diabetes care. <i>Diabetes Research and Clinical Practice</i> , 2015, 107, 1-8.	1.1	75
25	Endothelial dysfunction and inflammation predict development of diabetic nephropathy in the Irbesartan in Patients with Type 2 Diabetes and Microalbuminuria (IRMA 2) study. <i>Scandinavian Journal of Clinical and Laboratory Investigation</i> , 2008, 68, 731-738.	0.6	74
26	Spironolactone diminishes urinary albumin excretion in patients with type 1 diabetes and microalbuminuria: a randomized placebo-controlled crossover study. <i>Diabetic Medicine</i> , 2012, 29, e184-90.	1.2	71
27	Urinary proteomics predict onset of microalbuminuria in normoalbuminuric type 2 diabetic patients, a sub-study of the DIRECT-Protect 2 study. <i>Nephrology Dialysis Transplantation</i> , 2017, 32, gfw292.	0.4	66
28	Tissue Renin—Angiotensin Systems: A Unifying Hypothesis of Metabolic Disease. <i>Frontiers in Endocrinology</i> , 2014, 5, 23.	1.5	65
29	Noninvasive diagnosis of chronic kidney diseases using urinary proteome analysis. <i>Nephrology Dialysis Transplantation</i> , 2017, 32, gfw337.	0.4	62
30	Time course and mechanisms of the anti-hypertensive and renal effects of liraglutide treatment. <i>Diabetic Medicine</i> , 2015, 32, 343-352.	1.2	61
31	Effects of Dapagliflozin on Volume Status When Added to Renin—Angiotensin System Inhibitors. <i>Journal of Clinical Medicine</i> , 2019, 8, 779.	1.0	61
32	Impact of Baseline Renal Function on the Efficacy and Safety of Aliskiren Added to Losartan in Patients With Type 2 Diabetes and Nephropathy. <i>Diabetes Care</i> , 2010, 33, 2304-2309.	4.3	58
33	Initial Angiotensin Receptor Blockade—Induced Decrease in Albuminuria Is Associated With Long-Term Renal Outcome in Type 2 Diabetic Patients With Microalbuminuria. <i>Diabetes Care</i> , 2011, 34, 2078-2083.	4.3	58
34	Glucagon-like peptide 1 receptor agonist (GLP-1 RA): long-term effect on kidney function in patients with type 2 diabetes. <i>Journal of Diabetes and Its Complications</i> , 2015, 29, 670-674.	1.2	58
35	Baseline characteristics in the Aliskiren Trial in Type 2 Diabetes Using Cardio-Renal Endpoints (ALTITUDE). <i>JRAAS - Journal of the Renin-Angiotensin-Aldosterone System</i> , 2012, 13, 387-393.	1.0	56
36	Aliskiren in Combination with Losartan Reduces Albuminuria Independent of Baseline Blood Pressure in Patients with Type 2 Diabetes and Nephropathy. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2011, 6, 1025-1031.	2.2	53

#	ARTICLE	IF	CITATIONS
37	Is a reduction in albuminuria associated with renal and cardiovascular protection? A <i>post hoc</i> analysis of the <i>ALTITUDE</i> trial. <i>Diabetes, Obesity and Metabolism</i> , 2016, 18, 169-177.	2.2	49
38	The Impact of Sotagliflozin on Renal Function, Albuminuria, Blood Pressure, and Hematocrit in Adults With Type 1 Diabetes. <i>Diabetes Care</i> , 2019, 42, 1921-1929.	4.3	47
39	Efficacy and Safety of Dapagliflozin by Baseline Glycemic Status: A Prespecified Analysis From the DAPA-CKD Trial. <i>Diabetes Care</i> , 2021, 44, 1894-1897.	4.3	47
40	Symmetric and asymmetric dimethylarginine as risk markers of cardiovascular disease, all-cause mortality and deterioration in kidney function in persons with type 2 diabetes and microalbuminuria. <i>Cardiovascular Diabetology</i> , 2017, 16, 88.	2.7	41
41	High YKL-40 levels predict mortality in patients with type 2 diabetes. <i>Diabetes Research and Clinical Practice</i> , 2012, 96, 84-89.	1.1	39
42	Renal outcomes with aliskiren in patients with type 2 diabetes: a prespecified secondary analysis of the <i>ALTITUDE</i> randomised controlled trial. <i>Lancet Diabetes and Endocrinology</i> , 2016, 4, 309-317.	5.5	39
43	Effects of liraglutide on cardiovascular risk biomarkers in patients with type 2 diabetes and albuminuria: a sub-analysis of a randomized, placebo-controlled, double-blind, crossover trial. <i>Diabetes, Obesity and Metabolism</i> , 2017, 19, 901-905.	2.2	39
44	Soluble Urokinase Plasminogen Activator Receptor Predicts Cardiovascular Events, Kidney Function Decline, and Mortality in Patients With Type 1 Diabetes. <i>Diabetes Care</i> , 2019, 42, 1112-1119.	4.3	38
45	Prevention of microalbuminuria using early intervention with renin-angiotensin system inhibitors in patients with type 2 diabetes: A systematic review. <i>JRAAS - Journal of the Renin-Angiotensin-Aldosterone System</i> , 2016, 17, 147032031665204.	1.0	36
46	Prognosis and treatment of diabetic nephropathy: Recent advances and perspectives. <i>Nephrologie Et Therapeutique</i> , 2018, 14, S31-S37.	0.2	35
47	Effect of large weight reductions on measured and estimated kidney function. <i>BMC Nephrology</i> , 2017, 18, 52.	0.8	34
48	Optimal dose of lisinopril for renoprotection in type 1 diabetic patients with diabetic nephropathy: a randomised crossover trial. <i>Diabetologia</i> , 2009, 52, 46-49.	2.9	32
49	Optimal antiproteinuric dose of aliskiren in type 2 diabetes mellitus: a randomised crossover trial. <i>Diabetologia</i> , 2010, 53, 1576-1580.	2.9	30
50	24-hour central aortic systolic pressure and 24-hour central pulse pressure are related to diabetic complications in type 1 diabetes – a cross-sectional study. <i>Cardiovascular Diabetology</i> , 2013, 12, 122.	2.7	30
51	Changes in Albuminuria Predict Cardiovascular and Renal Outcomes in Type 2 Diabetes: A Post Hoc Analysis of the <i>LEADER</i> Trial. <i>Diabetes Care</i> , 2021, 44, 1020-1026.	4.3	30
52	Predicting albuminuria response to spironolactone treatment with urinary proteomics in patients with type 2 diabetes and hypertension. <i>Nephrology Dialysis Transplantation</i> , 2018, 33, gfw406.	0.4	29
53	Growth differentiation factor-15 and fibroblast growth factor-23 are associated with mortality in type 2 diabetes – An observational follow-up study. <i>PLoS ONE</i> , 2018, 13, e0196634.	1.1	29
54	The effects of dapagliflozin, metformin or exercise on glycaemic variability in overweight or obese individuals with prediabetes (the <i>PRE-D</i> Trial): a multi-arm, randomised, controlled trial. <i>Diabetologia</i> , 2021, 64, 42-55.	2.9	29

#	ARTICLE	IF	CITATIONS
55	Incidence of Ketoacidosis in the Danish Type 2 Diabetes Population Before and After Introduction of Sodiumâ€“Glucose Cotransporter 2 Inhibitorsâ€“ A Nationwide, Retrospective Cohort Study, 1995â€“2014. <i>Diabetes Care</i> , 2017, 40, e57-e58.	4.3	26
56	Ambulatory Tonometric Blood Pressure Measurements in Patients with Diabetes. <i>Diabetes Technology and Therapeutics</i> , 2012, 14, 453-456.	2.4	25
57	Development and validation of a brief, descriptive Danish pain questionnaire (BDDPQ). <i>Acta Anaesthesiologica Scandinavica</i> , 2004, 48, 486-490.	0.7	24
58	Elevated NT-proBNP and coronary calcium score in relation to coronary artery disease in asymptomatic type 2 diabetic patients with elevated urinary albumin excretion rate. <i>Nephrology Dialysis Transplantation</i> , 2011, 26, 3242-3249.	0.4	24
59	Plasma high-sensitivity troponin T predicts end-stage renal disease and cardiovascular and all-cause mortality in patients with type 1 diabetes and diabetic nephropathy. <i>Kidney International</i> , 2017, 92, 1242-1248.	2.6	24
60	Different patterns of secondâ€“line treatment in type 2 diabetes after metformin monotherapy in Denmark, Finland, Norway and Sweden (D360 Nordic): A multinational observational study. <i>Endocrinology, Diabetes and Metabolism</i> , 2018, 1, e00036.	1.0	24
61	Characteristics of highâ€“and lowâ€“risk individuals in the <sc>PRIORITY</sc> study: urinary proteomics and mineralocorticoid receptor antagonism for prevention of diabetic nephropathy in Type 2 diabetes. <i>Diabetic Medicine</i> , 2018, 35, 1375-1382.	1.2	24
62	Effect of dapagliflozin on cardiac function in people with type 2 diabetes and albuminuria â€“ A double blind randomized placebo-controlled crossover trial. <i>Journal of Diabetes and Its Complications</i> , 2020, 34, 107590.	1.2	24
63	Urinary renin and angiotensinogen in type 2 diabetes. <i>Journal of Hypertension</i> , 2013, 31, 1646-1652.	0.3	23
64	Urinary tubular biomarkers as predictors of kidney function decline, cardiovascular events and mortality in microalbuminuric type 2 diabetic patients. <i>Acta Diabetologica</i> , 2018, 55, 1143-1150.	1.2	23
65	Variability in response to albuminuriaâ€“lowering drugs: true or random?. <i>British Journal of Clinical Pharmacology</i> , 2017, 83, 1197-1204.	1.1	22
66	Improving peptide relative quantification in MALDI-TOF MS for biomarker assessment. <i>Proteomics</i> , 2013, 13, 2967-2975.	1.3	21
67	Levels of NT-proBNP, markers of low-grade inflammation, and endothelial dysfunction during spironolactone treatment in patients with diabetic kidney disease. <i>JRAAS - Journal of the Renin-Angiotensin-Aldosterone System</i> , 2013, 14, 161-166.	1.0	21
68	Number and Frequency of Albuminuria Measurements in Clinical Trials in Diabetic Nephropathy. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2015, 10, 410-416.	2.2	21
69	Impact of aliskiren treatment on urinary aldosterone levels in patients with type 2 diabetes and nephropathy: an AVOID substudy. <i>JRAAS - Journal of the Renin-Angiotensin-Aldosterone System</i> , 2012, 13, 118-121.	1.0	20
70	A prediction of the renal and cardiovascular efficacy of aliskiren in ALTITUDE using short-term changes in multiple risk markers. <i>European Journal of Preventive Cardiology</i> , 2014, 21, 434-441.	0.8	19
71	Interpretation of HbA_{1c} in primary care and potential influence of anaemia and chronic kidney disease: an analysis from the Copenhagen Primary Care Laboratory (CopLab) Database. <i>Diabetic Medicine</i> , 2018, 35, 1700-1706.	1.2	19
72	Mitigating risk of aldosterone in diabetic kidney disease. <i>Current Opinion in Nephrology and Hypertension</i> , 2020, 29, 145-151.	1.0	19

#	ARTICLE	IF	CITATIONS
73	Toeâ€˜brachial index as a predictor of cardiovascular disease and all-cause mortality in people with type 2 diabetes and microalbuminuria. <i>Diabetologia</i> , 2017, 60, 1883-1891.	2.9	18
74	Protocol for a randomised controlled trial of the effect of dapagliflozin, metformin and exercise on glycaemic variability, body composition and cardiovascular risk in prediabetes (the PRE-D Trial). <i>BMJ Open</i> , 2017, 7, e013802.	0.8	17
75	Urinary albumin and 8-oxo-7,8-dihydroguanosine as markers of mortality and cardiovascular disease during 19 years after diagnosis of type 2 diabetes â€˜ A comparative study of two markers to identify high risk patients. <i>Redox Biology</i> , 2017, 13, 363-369.	3.9	17
76	Uric acid is not associated with diabetic nephropathy and other complications in type 1 diabetes. <i>Nephrology Dialysis Transplantation</i> , 2019, 34, 659-666.	0.4	17
77	Urinary Proteomics and Precision Medicine for Chronic Kidney Disease: Current Status and Future Perspectives. <i>Proteomics - Clinical Applications</i> , 2019, 13, 1800176.	0.8	16
78	A Validated Prediction Model for End-Stage Kidney Disease in Type 1 Diabetes. <i>Diabetes Care</i> , 2021, 44, 901-907.	4.3	16
79	Drugâ€˜drug interaction between warfarin and statins: A Danish cohort study. <i>British Journal of Clinical Pharmacology</i> , 2021, 87, 694-699.	1.1	15
80	Pleiotropic effects of liraglutide treatment on renal risk factors in type 2 diabetes: Individual effects of treatment. <i>Journal of Diabetes and Its Complications</i> , 2017, 31, 162-168.	1.2	13
81	Omics research in diabetic kidney disease: new biomarker dimensions and new understandings?. <i>Journal of Nephrology</i> , 2020, 33, 931-948.	0.9	13
82	Assessment of the sublingual microcirculation with the GlycoCheck system: Reproducibility and examination conditions. <i>PLoS ONE</i> , 2020, 15, e0243737.	1.1	13
83	Comments on the 2019 ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases. <i>European Heart Journal</i> , 2020, 41, 328-328.	1.0	12
84	Linking Kidney and Cardiovascular Complications in Diabetesâ€˜Impact on Prognostication and Treatment: The 2019 Edwin Bierman Award Lecture. <i>Diabetes</i> , 2021, 70, 39-50.	0.3	12
85	Sequential RAAS Blockade: Is It Worth the Risk?. <i>Advances in Chronic Kidney Disease</i> , 2014, 21, 159-165.	0.6	11
86	Multifactorial intervention to prevent cardiovascular disease in patients with early rheumatoid arthritis: protocol for a multicentre randomised controlled trial. <i>BMJ Open</i> , 2016, 6, e009134.	0.8	11
87	Direct renin inhibition in chronic kidney disease. <i>British Journal of Clinical Pharmacology</i> , 2012, 76, n/a-n/a.	1.1	10
88	The influence of pharmaceutically induced weight changes on estimates of renal function: A patient-level pooled analysis of seven randomised controlled trials of glucose lowering medication. <i>Journal of Diabetes and Its Complications</i> , 2015, 29, 1146-1151.	1.2	10
89	Nâ€˜terminal proâ€˜brain natriuretic peptide (NTâ€˜proBNP) predicts the cardioâ€˜renal response to aliskiren in patients with type 2 diabetes at high renal and cardiovascular risk. <i>Diabetes, Obesity and Metabolism</i> , 2018, 20, 2899-2904.	2.2	10
90	Study rationale and design of the EANITIATE study (EmpAgliflozin compared to NPH Insulin for sTerold) Tj ETQq0 0 0 rgBT /Overlock 10 T empagliflozin compared with NPH-insulin in patients with newly onset diabetes following initiation of glucocorticoid treatment. <i>BMC Endocrine Disorders</i> , 2020, 20, 86.	0.9	10

#	ARTICLE	IF	CITATIONS
91	Cardiovascular and renal outcomes by baseline albuminuria status and renal function: Results from the LEADER randomized trial. <i>Diabetes, Obesity and Metabolism</i> , 2020, 22, 2077-2088.	2.2	10
92	Postural Stability after Inguinal Herniorrhaphy under Local Infiltration Anaesthesia. <i>The European Journal of Surgery</i> , 2001, 167, 449-452.	1.0	9
93	Serum uric acid and progression of diabetic nephropathy in type 1 diabetes. <i>Journal of Diabetes and Its Complications</i> , 2018, 32, 470-473.	1.2	9
94	Application of urinary proteomics as possible risk predictor of renal and cardiovascular complications in patients with type 2-diabetes and microalbuminuria. <i>Journal of Diabetes and Its Complications</i> , 2018, 32, 1133-1140.	1.2	9
95	Pleiotropic effects of liraglutide in patients with type 2 diabetes and moderate renal impairment: Individual effects of treatment. <i>Diabetes, Obesity and Metabolism</i> , 2019, 21, 1261-1265.	2.2	9
96	No effects of dapagliflozin, metformin or exercise on plasma glucagon concentrations in individuals with prediabetes: A post hoc analysis from the randomized controlled PRECISE trial. <i>Diabetes, Obesity and Metabolism</i> , 2021, 23, 530-539.	2.2	9
97	Risk factor management of type 2 diabetic patients in primary care in the Scandinavian countries between 2003 and 2015. <i>Primary Care Diabetes</i> , 2021, 15, 262-268.	0.9	9
98	Long-Term Effects of Irbesartan Treatment and Smoking on Nucleic Acid Oxidation in Patients With Type 2 Diabetes and Microalbuminuria. <i>Diabetes Care</i> , 2011, 34, 1192-1198.	4.3	8
99	Renin angiotensin system blockade reduces urinary levels of soluble urokinase plasminogen activator receptor (suPAR) in patients with type 2 diabetes. <i>Journal of Diabetes and Its Complications</i> , 2016, 30, 1440-1442.	1.2	8
100	The effect of liraglutide and sitagliptin on oxidative stress in persons with type 2 diabetes. <i>Scientific Reports</i> , 2021, 11, 10624.	1.6	8
101	Pooled Analysis of Multiple Crossover Trials To Optimize Individual Therapy Response to Renin-Angiotensin-Aldosterone System Intervention. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2017, 12, 1804-1813.	2.2	7
102	Visit-to-visit variability of clinical risk markers in relation to long-term complications in type 1 diabetes. <i>Diabetic Medicine</i> , 2021, 38, e14459.	1.2	7
103	Is Time-Restricted Eating Safe in the Treatment of Type 2 Diabetes? A Review of Intervention Studies. <i>Nutrients</i> , 2022, 14, 2299.	1.7	7
104	Incidence of New-Onset Type 2 Diabetes After Cancer: A Danish Cohort Study. <i>Diabetes Care</i> , 2022, 45, e105-e106.	4.3	7
105	Irbesartan treatment does not influence plasma levels of the advanced glycation end products N ^ε (1-carboxymethyl)lysine and N ^ε (1-carboxyethyl)lysine in patients with type 2 diabetes and microalbuminuria. A randomized controlled trial. <i>Nephrology Dialysis Transplantation</i> , 2011, 26, 3573-3577.	0.4	6
106	Improving the effectiveness of short-term courses for multidisciplinary health care professionals. <i>Practical Diabetes</i> , 2015, 32, 180-185.	0.1	6
107	Effect of weight reductions on estimated kidney function: Post-hoc analysis of two randomized trials. <i>Journal of Diabetes and Its Complications</i> , 2017, 31, 1164-1168.	1.2	6
108	The effect of uric acid lowering treatment on albuminuria and renal function in Type 1 diabetes: a randomized clinical trial. <i>Diabetic Medicine</i> , 2018, 35, 392-393.	1.2	6

#	ARTICLE	IF	CITATIONS
109	Achieving a useful and person-centred diabetes consultation is a shared responsibility between diabetologists and people with diabetes: a qualitative study of perspectives from people with type 1 diabetes. <i>Diabetic Medicine</i> , 2021, 38, e14382.	1.2	6
110	Nordic Longitudinal Data from Electronic Medical Records and Full Population National Registers: Unique Opportunities for New Insights in Benefit of Diabetes Patients. <i>Value in Health</i> , 2015, 18, A726.	0.1	5
111	YKL-40 in dialysis patients: another candidate in the quest for useful biomarkers in nephrology. <i>Kidney International</i> , 2018, 93, 21-22.	2.6	5
112	Inflammation Leads the Way on the ROADMAP to Diabetic Kidney Disease. <i>Kidney International Reports</i> , 2019, 4, 1362-1365.	0.4	5
113	Irbesartan treatment does not influence plasma levels of the dicarbonyls methylglyoxal, glyoxal and 3-deoxyglucosone in participants with type 2 diabetes and microalbuminuria: An IRMA2 sub-study. <i>Diabetic Medicine</i> , 2021, 38, e14405.	1.2	5
114	Importance of standardizing renal outcomes in clinical trials: illustration by recent sodium glucose cotransporter 2 inhibitor studies. <i>Kidney International</i> , 2021, 99, 768-770.	2.6	5
115	A narrative review of new treatment options for chronic kidney disease in type 2 diabetes. <i>Annals of Translational Medicine</i> , 2021, 9, 716-716.	0.7	5
116	The importance of addressing multiple risk markers in type 2 diabetes: Results from the LEADER and SUSTAIN 6 trials. <i>Diabetes, Obesity and Metabolism</i> , 2022, 24, 281-288.	2.2	5
117	Copeptin and renal function decline, cardiovascular events and mortality in type 1 diabetes. <i>Nephrology Dialysis Transplantation</i> , 2020, , .	0.4	5
118	Impact of random variation in albuminuria and estimated glomerular filtration rate on patient enrolment and duration of clinical trials in nephrology. <i>Diabetes, Obesity and Metabolism</i> , 2022, 24, 983-990.	2.2	5
119	Sodium-glucose cotransporter 2 inhibitors as adjunct therapy for type 1 diabetes and the benefit on cardiovascular and renal disease evaluated by Steno risk engines. <i>Journal of Diabetes and Its Complications</i> , 2022, 36, 108257.	1.2	5
120	Higher Parathyroid Hormone Level Is Associated With Increased Arterial Stiffness in Type 1 Diabetes. <i>Diabetes Care</i> , 2017, 40, e32-e33.	4.3	4
121	Lipoprotein(a) and renal function decline, cardiovascular disease and mortality in type 2 diabetes and microalbuminuria. <i>Journal of Diabetes and Its Complications</i> , 2020, 34, 107593.	1.2	4
122	Improving frequency of urinary albumin testing in type 2 diabetes in primary care – An analysis of cross-sectional studies in Denmark. <i>Primary Care Diabetes</i> , 2021, 15, 1007-1011.	0.9	4
123	Impact of glycaemic control on the effect of direct renin inhibition in the AVOID study. <i>JRAAS - Journal of the Renin-Angiotensin-Aldosterone System</i> , 2012, 13, 250-253.	1.0	3
124	Discrepancy Between Tonometric Ambulatory and Cuff-Based Office Blood Pressure Measurements in Patients With Type 1 Diabetes. <i>Journal of Clinical Hypertension</i> , 2012, 14, 686-693.	1.0	3
125	Effects of RAS inhibitors on diabetic retinopathy. <i>Lancet Diabetes and Endocrinology</i> , 2015, 3, 315-316.	5.5	3
126	Increasing ESKD in Diabetes in the Land Down Under: What Can Be Done, We Must Wonder. <i>American Journal of Kidney Diseases</i> , 2019, 73, 293-296.	2.1	3

#	ARTICLE	IF	CITATIONS
127	Oral treatment of glucocorticoid-induced diabetes mellitus: A systematic review. International Journal of Clinical Practice, 2020, 74, e13529.	0.8	3
128	Endothelial glycocalyx and cardio-renal risk factors in type 1 diabetes. PLoS ONE, 2021, 16, e0254859.	1.1	3
129	Acute and Long-Term Treatment With Dapagliflozin and Association With Serum Soluble Urokinase Plasminogen Activator Receptor. Frontiers in Pharmacology, 2022, 13, 799915.	1.6	3
130	Improvements in albuminuria and chronic kidney disease progression with the appetite suppressant lorcaserin. Kidney International, 2019, 95, 1287-1288.	2.6	2
131	A large remaining potential in lipid-lowering drug treatment in the type 2 diabetes population: A Danish nationwide cohort study. Diabetes, Obesity and Metabolism, 2021, 23, 2354-2363.	2.2	2
132	Empagliflozin reduces albuminuria—a promise for better cardiorenal protection from the EMPA-REG OUTCOME trial. Annals of Translational Medicine, 2017, 5, 478-478.	0.7	1
133	FC 058THE IMPORTANCE OF ADDRESSING MULTIPLE RISK MARKERS IN TYPE 2 DIABETES: RESULTS FROM THE LEADER AND SUSTAIN 6 TRIALS. Nephrology Dialysis Transplantation, 2021, 36, .	0.4	1
134	What Have We Learned so Far From the Use of Sodium-Glucose Cotransporter 2 Inhibitors in Clinical Practice?. Advances in Chronic Kidney Disease, 2021, 28, 290-297.	0.6	1
135	Aldosterone Blockade Added to Renin-Angiotensin System Blockade to Reduce Albuminuria—A Path for Improved Renoprotection?. American Journal of the Medical Sciences, 2018, 355, 407-408.	0.4	0
136	Title is missing!. , 2020, 15, e0243737.		0
137	Title is missing!. , 2020, 15, e0243737.		0
138	Title is missing!. , 2020, 15, e0243737.		0
139	Title is missing!. , 2020, 15, e0243737.		0
140	Title is missing!. , 2020, 15, e0243737.		0
141	Title is missing!. , 2020, 15, e0243737.		0
142	Title is missing!. , 2020, 15, e0243737.		0
143	Title is missing!. , 2020, 15, e0243737.		0